Maria Zannes and her company BioAffinity Technologies are seeking to up the game on lung cancer detection. Here’s how.
Maria Zannes’ path to a leading role in the medtech field wasn’t quite a conventional one.
The one-time aspiring journalist carved out a role on Capitol Hill, first as an aide, then as a lobbyist, plus a stint running a trade group. During all that, she managed to pick up her law degree, too.
However, when her brother was diagnosed with glioblastoma, Zannes left Washington, D.C., for New Mexico. There, she came across a technology that had come out of Los Alamos National Laboratory which used certain compounds to label cancer cells, piquing her interests both on a personal and professional level.
Zannes has now been involved in this technology for 10 years or so, developing a test for early lung cancer, and with plans to commercialize the noninvasive test this year.
Zannes spoke to MassDevice recently, discussing her background, her company, BioAffinity Technologies and its work, plus being a woman in medtech.